Pre-exposure prophylaxis (PrEP), as an effective means to reduce new HIV infections in high-risk populations, is listed as ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.

The EU has approved an injectable HIV drug offering a two-month dosage schedule, marking a breakthrough in treatment ...

It was supposed to be a banner year in the fight against the HIV epidemic. Nationwide infection rates were gradually falling, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...